Gemma Salvadó
21 – 30 of 32
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
- Contribution to journal › Article
- 2023
-
Mark
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients : A multi-cohort study
- Contribution to journal › Article
-
Mark
Quantification of [18F]florbetaben amyloid-PET imaging in a mixed memory clinic population : The ABIDE project
- Contribution to journal › Article
-
Mark
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
- Contribution to journal › Article
-
Mark
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
- Contribution to journal › Article
-
Mark
APOE -ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals
- Contribution to journal › Article
-
Mark
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
- Contribution to journal › Article
-
Mark
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
- Contribution to journal › Article
- 2022
-
Mark
Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic : what is the role of stress perception, stress resilience, and β-amyloid?
- Contribution to journal › Article
-
Mark
Quantifying AD-related brain amyloid with linearised progression models : model-based vs. data-based.
- Contribution to journal › Debate/Note/Editorial
